JNK contributes to temozolomide resistance of stem-like glioblastoma cells via regulation of MGMT expression

International Journal of Oncology

Volumn 44, Issue 2, 2014, Pages 591-599

  Okada, Masashi ^a   Sato, Atsushi ^a   Shibuya, Keita ^a   Watanabe, Eriko ^a,b,c   Seino, Shizuka ^a,b,c   Suzuki, Shuhei ^a   Seino, Manabu ^a   Narita, Yoshitaka ^d   Shibui, Soichiro ^d   Kayama, Takamasa ^a   Kitanaka, Chifumi ^a,b,c  

^a YAMAGATA UNIVERSITY   (Japan)

^b YAMAGATA UNIVERSITY   (Japan)

^c JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Cancer stem cell; Chemoresistance; Combination chemotherapy; Glioma initiating cell; JNK; O6 methylguanine DNA methyltransferase

Indexed keywords

ANTHRACENES; ANTINEOPLASTIC AGENTS, ALKYLATING; BLOTTING, WESTERN; DACARBAZINE; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; MAP KINASE KINASE 4; NEOPLASTIC STEM CELLS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY; TUMOR SUPPRESSOR PROTEINS;

EID: 84894483694     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2209     Document Type: Article

References (38)

1. Wen PY and Kesari S: Malignant gliomas in adults. N Engl J Med 359: 492-507, 2008.
2. Khasraw M and Lassman AB: Advances in the treatment of malignant gliomas. Curr Oncol Rep 12: 26-33, 2010.
3. Yu Y, Ramena G and Elble RC: The role of cancer stem cells in relapse of solid tumors. Front Biosci (Elite Ed) 4: 1528-1541, 2012.
4. Binda E, Visioli A, Reynolds B and Vescovi AL: Heterogeneity of cancer-initiating cells within glioblastoma. Front Biosci (Schol Ed) 4: 1235-1248, 2012.
5. Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature 414: 105-111, 2001. (Pubitemid 33041634)
6. Malik B and Nie D: Cancer stem cells and resistance to chemo and radio therapy. Front Biosci (Elite Ed) 4: 2142-2149, 2012.
7. Beier D, Schulz JB and Beier CP: Chemoresistance of glioblastoma cancer stem cells - much more complex than expected. Mol Cancer 10: 128, 2011.
8. 6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem 96: 766-776, 2006.
9. 6- methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 26: 4189-4199, 2008.
10. Blough MD, Westgate MR, Beauchamp D, et al: Sensitivity to temozolomide in brain tumor initiating cells. Neurooncology 12: 756-760, 2010.
11. 6- methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients. Neurooncology 12: 28-36, 2010.
12. Kato T, Natsume A, Toda H, et al: Efficient delivery of liposome-mediated MGMT-siRNA reinforces the cytotoxity of temozolomide in GBM-initiating cells. Gene Ther 17: 1363-1371, 2010.
13. Ikushima H, Todo T, Ino Y, Takahashi M, Miyazawa K and Miyazono K: Autocrine TGF-beta signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors. Cell Stem Cell 5: 504-514, 2009.
14. Matsuda K, Sato A, Okada M, et al: Targeting JNK for therapeutic depletion of stem-like glioblastoma cells. Sci Rep 2: 516, 2012.
15. Sato A, Sunayama J, Okada M, et al: Glioma-initiating cell elimination by metformin activation of FOXO3 via AMPK. Stem Cells Transl Med 1: 811-824, 2012.
16. Hart MG, Garside R, Rogers G, Stein K and Grant R: Temozolomide for high grade glioma. Cochrane Database Syst Rev 4: CD007415, 2013.
17. Hegi ME, Diserens AC, Godard S, et al: Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 10: 1871-1874, 2004. (Pubitemid 38375541)
18. Sato A, Sunayama J, Matsuda K, et al: MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis. Stem Cells 29: 1942-1951, 2011.
19. Ciceroni C, Bonelli M, Mastrantoni E, et al: Type-3 metabotropic glutamate receptors regulate chemoresistance in glioma stem cells, and their levels are inversely related to survival in patients with malignant gliomas. Cell Death Differ 20: 396-407, 2013.
20. Persano L, Pistollato F, Rampazzo E, et al: BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1alpha stability and MGMT expression. Cell Death Dis 3: e412, 2012.
21. Siebzehnrubl FA, Silver DJ, Tugertimur B, et al: The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance. EMBO Mol Med 5: 1196-1212, 2013.
22. Ohba S, Hirose Y, Kawase T and Sano H: Inhibition of c-Jun N-terminal kinase enhances temozolomide-induced cytotoxicity in human glioma cells. J Neurooncol 95: 307-316, 2009.
23. Kanzawa T, Germano IM, Kondo Y, Ito H, Kyo S and Kondo S: Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide. Br J Cancer 89: 922-929, 2003. (Pubitemid 37175817)
24. Aghi M, Rabkin S and Martuza RL: Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. J Natl Cancer Inst 98: 38-50, 2006. (Pubitemid 43057091)
25. Nadkarni A, Shrivastav M, Mladek AC, et al: ATM inhibitor KU-55933 increases the TMZ responsiveness of only inherently TMZ sensitive GBM cells. J Neurooncol 110: 349-357, 2012.
26. Miyazawa K: A negative regulator or just an unconcerned passerby: phosphoinositide 3-kinase signalling in IL-12 production. J Biochem 152: 497-499, 2012.
27. Jemaa M, Vitale I, Kepp O, et al: Selective killing of p53-deficient cancer cells by SP600125. EMBO Mol Med 4: 500-514, 2012.
28. Schmidt M, Budirahardja Y, Klompmaker R and Medema RH: Ablation of the spindle assembly checkpoint by a compound targeting Mps1. EMBO Rep 6: 866-872, 2005. (Pubitemid 43108678)
29. Kohsaka S, Wang L, Yachi K, et al: STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression. Mol Cancer Ther 11: 1289-1299, 2012.
30. 6-methylguanine-DNA methyltransferase (MGMT) via interaction with Sp1 transcription factor. Anticancer Res 29: 3741-3750, 2009.
31. 6-methylguanine-DNA methyltransferase via protein kinase C-mediated signaling. Cancer Res 58: 3950-3956, 1998.
32. 6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling. Carcinogenesis 34: 2206-2217, 2013.
33. Lavon I, Fuchs D, Zrihan D, et al: Novel mechanism whereby nuclear factor kappaB mediates DNA damage repair through regulation of O(6)-methylguanine-DNA- methyltransferase. Cancer Res 67: 8952-8959, 2007. (Pubitemid 47437473)
34. Chuang JY, Wang YT, Yeh SH, Liu YW, Chang WC and Hung JJ: Phosphorylation by c-Jun NH2-terminal kinase 1 regulates the stability of transcription factor Sp1 during mitosis. Mol Biol Cell 19: 1139-1151, 2008.
35. Wang SA, Chuang JY, Yeh SH, et al: Heat shock protein 90 is important for Sp1 stability during mitosis. J Mol Biol 387: 1106-1119, 2009.
36. Noguchi K, Kitanaka C, Yamana H, Kokubu A, Mochizuki T and Kuchino Y: Regulation of c-Myc through phosphorylation at Ser-62 and Ser-71 by c-Jun N-terminal kinase. J Biol Chem 274: 32580-32587, 1999. (Pubitemid 129535283)
37. Kitanaka C, Sato A and Okada M: JNK signaling in the control of the tumor-initiating capacity associated with cancer stem cells. Genes Cancer: Jan 22, 2013 (Epub ahead of print). doi: 10.1177/1947601912474892.
38. Yoon CH, Kim MJ, Kim RK, et al: c-Jun N-terminal kinase has a pivotal role in the maintenance of self-renewal and tumorigenicity in glioma stem-like cells. Oncogene 31: 4655-4666, 2012.